Baxter International Inc. (BAX) Financial Statements
Historical financial data — 40 statements covering FY2016–FY2025
Baxter offers a variety of medical supplies and equipment to providers. From its legacy operations, Baxter sells injectable therapies for use in care settings, including IV pumps, administrative se...
Baxter International Inc.'s revenue increased 5.7% year over year, from $10.64B to $11.24B.
Net income decreased 47.5% over the same period, from $-649.0M to $-957.0M.
Over the 9-year period from FY2016 to FY2025, revenue grew by 11% in total.
Total debt decreased by 100.0% to $1.0M.
The debt-to-equity ratio stands at 0.00, indicating a conservative leverage profile.
Operating cash flow declined 17.1% to $845.0M.
Baxter International Inc. maintains a negative net profit margin of -8.5%.
Recent Financial Statements
| Period | Revenue | Net Income | Gross Profit | EBIT | Op. Cash Flow | Total Assets | Total Debt | Equity |
|---|---|---|---|---|---|---|---|---|
| Q3 FY2023 | $10.93B+51.4% | $2.41B | $3.50B | $61.0M | $1.20B | $30.66B | $14.58B | $8.10B |
| Q1 FY2024 | $3.59B-67.1% | $37.0M | $1.39B | $187.0M | $163.0M | $27.79B | $13.73B | $8.17B |
| Q2 FY2024 | $7.40B+106.1% | $-277.0M | $2.82B | $-5.0M | $278.0M | $26.31B | $12.90B | $7.64B |
| Q3 FY2024 | $7.88B+6.5% | $-137.0M | $3.02B | $449.0M | $531.0M | $26.68B | $12.94B | $7.87B |
| Q1 FY2025 | $2.63B-66.7% | $126.0M | $861.0M | $58.0M | $-193.0M | $21.30B | $11.0M | $7.08B |
| Q2 FY2025 | $5.43B+107.0% | $217.0M | $1.85B | $249.0M | $24.0M | $21.05B | $6.0M | $7.32B |
| Q3 FY2025 | $8.27B+52.2% | $171.0M | $2.80B | $421.0M | $261.0M | $21.07B | $4.0M | $7.24B |
| Q1 FY2026 | $2.70B-67.3% | $-15.0M | $891.0M | $66.0M | $213.0M | $19.85B | $0 | $6.04B |
Balance Sheet Summary (Latest Period)
Total Assets
$20.05B
Total Liabilities
$13.95B
Total Equity
$6.13B
Cash & Equivalents
$1.97B
Total Debt
$1.0M
Current Assets
$6.87B
Current Liabilities
$2.97B
Retained Earnings
$13.71B